The Serum Institute of India (SII), which is conducting Oxford-AstraZeneca coronavirus vaccine phase 2-3 trials in India, has said that the Indian trials of the vaccine are continuing and they can't comment on the UK trials which have been paused after a patient developed unexplained illness. Oxford-AstraZeneca vaccine that will be called Covishiled in India, is expected to the first vaccine that may be launched in the coming months, optimistically in the first quarter of 2021.
"We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing and we have faced no issues at all," Serum Institute of India on reports on AstraZeneca halting the trials.
The development came after AstraZeneca had put leading coronavirus vaccine trials on hold over safety concern, Reuters reported.